TwikUp Brief
Health Canada recalled several lots of Dr. Reddy’s Semaglutide Injection after an impurity was found to be out of specification.
The affected lots include 7000544, 7000545, 7000546, 7000542, 7000543, 7000624, 7000628 and 7000629.
People with affected products should verify their lot number and consult a healthcare provider before discontinuing use.
The recall was issued because an impurity is out of specification in all lots of the affected products.
Health Canada classifies the action as a Type II health product recall under health products and drugs.
The recall was originally published on August 27, 2026, and applies to products from Dr. Reddy's Laboratories Canada Inc. (Health Canada)
The recall covers two product listings with the same semaglutide injection strength.
The first affected product has DIN 02567806 and includes lots:
The second affected product has DIN 02567814 and includes lots:
Consumers should check the lot number on their product to determine whether it is included in the recall. (Health Canada)
Health Canada advises people to first verify whether their product is affected.
If the product is part of the recall, the agency says consumers should consult their healthcare provider before discontinuing use or if they have any health concerns.
People can also contact the recalling firm if they have questions about the recall. (Health Canada)
Health Canada does not tell consumers to simply stop taking the affected product on their own.
Instead, the agency specifically advises people to consult their healthcare provider prior to discontinuing use of the affected product.
Anyone who is concerned about their treatment or has health-related questions should speak with their healthcare provider. (Health Canada)
The first step is to check the product packaging for the relevant identification information and compare the lot number with Health Canada's recall notice.
The affected lots listed by Health Canada are 7000544, 7000545, 7000546, 7000542, 7000543, 7000624, 7000628 and 7000629. (Health Canada)
If the lot number matches one of the recalled lots, consumers should contact their healthcare provider before making changes to their treatment.
The recalling firm is Dr. Reddy's Laboratories Canada Inc., based in Mississauga, Ontario.
The market authorization holder listed by Health Canada is DR REDDY'S LABORATORIES LTD.
The recall applies at the retailer level, according to Health Canada's notice. (Health Canada)
Health Canada has classified the action as a Type II health product recall.
The notice identifies the issue as a product-quality concern involving an impurity that is outside specification.
Health Canada lists the recall under Health products - Drugs and says the audience includes the general public, healthcare professionals and industry. (Health Canada)
Health Canada advises Canadians to report health product-related side effects to the agency.
Consumers can also report other health product safety complaints through Health Canada's reporting system.
The agency encourages people with concerns about the recalled product to contact their healthcare provider and follow the official recall instructions. (Health Canada)
Health Canada identifies the issue as a product-quality concern involving an impurity outside specification.
The recall does not cover every semaglutide product.
The notice specifically identifies certain lots from Dr. Reddy's Laboratories Canada Inc., which is why checking the lot number is important.
The most important step for consumers is to determine whether their product is included in the affected lots.
If it is, Health Canada recommends speaking with a healthcare provider before discontinuing use.
Consumers can contact the recalling firm if they have questions about the affected product. (Health Canada)
For now, the official notice identifies the affected products, lot numbers and recommended actions for consumers.
Anyone using Semaglutide Injection should check their product information rather than assuming that every semaglutide product is part of the recall.
Health Canada has recalled several lots of Dr. Reddy's Laboratories Canada Semaglutide Injection after identifying an impurity that is outside specification.
The recall covers two product listings and eight affected lot numbers.
For Canadians, the key point is that not every semaglutide product is included. Consumers should check their lot number against Health Canada's official list and consult their healthcare provider before discontinuing use if their product is affected.
Health Canada advises consumers to rely on the official recall notice and consult a healthcare provider before discontinuing an affected product.
The recall does not apply to every Semaglutide Injection product. Health Canada has identified specific lots affected by the quality issue, so consumers should check their product information against the official recall list before taking any action.
Verified reading
Open the original material in a new tab.
Health Canada recalled certain lots because an impurity was found to be out of specification in all affected lots.
The affected lots are 7000544, 7000545, 7000546, 7000542, 7000543, 7000624, 7000628, and 7000629.
Health Canada advises consumers to consult their healthcare provider before discontinuing use of the affected product.
The recalling firm is Dr. Reddy's Laboratories Canada Inc. Health Canada published the recall as a Type II health product recall.
Consumers should check their product's lot number and compare it with the affected lot numbers listed in Health Canada's official recall notice. If the product is affected, Health Canada recommends consulting a healthcare provider before discontinuing use.
